-
Pharmacokinetics of fondaparinux 1.5 mg once daily in a real-world cohort of ...
International audience -
Development of an oral form of fondaparinux
Since its introduction in the market in 2002, fondaparinux (Arixtra®) is a drug of choice in the anticoagulant therapy. Its structure corresponds to the heparin... -
Development of inactive modified antithrombin as an antidote to heparin antic...
Unfractionnated heparin (UFH), low molecular weight heparins (LMWH), and fondaparinux are used therapeutically as anticoagulants. They potentiate antithrombin (AT): a...
